Virtu Financial LLC Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Virtu Financial LLC purchased a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 32,000 shares of the company’s stock, valued at approximately $289,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Delcath Systems in the 3rd quarter valued at approximately $102,000. Barclays PLC bought a new position in shares of Delcath Systems in the third quarter worth $104,000. Jane Street Group LLC acquired a new position in shares of Delcath Systems during the third quarter valued at $110,000. Riverwater Partners LLC acquired a new position in shares of Delcath Systems during the third quarter valued at $161,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Delcath Systems during the second quarter valued at about $370,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Price Performance

Shares of DCTH opened at $11.94 on Wednesday. The firm’s 50 day moving average is $10.62 and its 200-day moving average is $9.20. Delcath Systems, Inc. has a 12-month low of $3.12 and a 12-month high of $13.30. The stock has a market capitalization of $381.77 million, a P/E ratio of -8.84 and a beta of 0.85.

Wall Street Analyst Weigh In

DCTH has been the subject of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Stephens reissued a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and an average target price of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.